In Segment A, individuals will acquire different doses and schedules of oral ABBV-744 tablet to detect Protected dosing program. Additional individuals will be enrolled on the determined monotherapy dosign program. In Phase B, participants will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment C, https://emilianoiwhse.blogpayz.com/32138256/details-fiction-and-abbv-744-in-acute-myeloid-leukemia-aml